Silica
Silica (silicon dioxide, SiO2) is a ubiquitous trace mineral present in the human body at total tissue concentrations of approximately 7 grams, with the highest concentrations found in bone, connective tissue, skin, hair, and nails. As bioavailable orthosilicic acid (Si(OH)4), dietary silicon is proposed to support collagen cross-linking, glycosaminoglycan synthesis, and the structural integrity of connective tissue through interactions with hydroxyl groups on proline and hydroxyproline residues in the COL1A1-encoded collagen alpha-1(I) chain. Clinical evidence for silica supplementation is modest and largely limited to trials in hair, nail, and skin quality endpoints, with some suggestive data for bone density in postmenopausal women. The evidence base is substantially less robust than for calcium, vitamin D, or collagen peptides in bone and connective tissue health, and silica should be considered a supportive trace mineral intervention rather than a primary therapeutic agent.
Key Takeaways
- •Silicon exists in biological systems primarily as orthosilicic acid (OSA, Si(OH)4), the monomeric soluble form that is absorbed from the gastrointestinal tract and crosses cell membranes. Dietary silicon sources vary enormously in bioavailability: plant silica in phytoliths (rigid silica bodies in plant cell walls) has very low bioavailability (less than 5 percent), while choline-stabilized orthosilicic acid (ch-OSA) supplements achieve absorption rates of 50 to 65 percent, making the form and source of silicon supplementation pharmacologically critical. Colloidal silica and silicic acid from water are intermediate in bioavailability.
- •The proposed mechanism for silica support of collagen integrity involves interaction between orthosilicic acid and the proline residues in the collagen triple helix, specifically at the Gly-Pro-Hyp repeating sequence that is the structural hallmark of the COL1A1-encoded type I collagen. Silicon is proposed to facilitate the enzymatic hydroxylation of proline to hydroxyproline by prolyl hydroxylase, and to support the subsequent cross-linking of collagen fibrils by lysyl oxidase. These interactions are mechanistically plausible given silicon's known role as a cofactor in other hydroxylation reactions, but definitive biochemical proof in isolated human collagen systems remains limited.
- •The most rigorous clinical trial for silica in hair and nail quality is the randomized double-blind study by Barel et al. (2005, Archives of Dermatological Research, n=48) examining choline-stabilized orthosilicic acid (ch-OSA) supplementation in women with fine hair. After 9 months of 10 mg/day ch-OSA, hair tensile strength (elastic gradient and break load) and hair brittleness improved significantly compared to placebo, with a trend toward increased hair thickness. Nail quality measures including brittleness also improved in the ch-OSA group. This trial represents the best evidence for silica supplementation in hair and nail quality but is limited by its relatively small sample size.
- •Bone health represents an area with suggestive but inconclusive evidence for silicon supplementation. Epidemiological data from the Framingham Offspring Study found that dietary silicon intake was positively associated with cortical bone mineral density in men and premenopausal women below age 50 (p less than 0.05), but not in postmenopausal women. This age and sex-specificity suggests that silicon bone effects may be estrogen-dependent or more relevant during active bone formation than during postmenopausal bone loss. Randomized trials of silicon supplementation specifically for bone density are limited; the evidence base for silicon in bone health is substantially weaker than for calcium, vitamin D3, or bisphosphonates.
- •Horsetail (Equisetum arvense) is the most commonly used botanical source of silica in supplements, containing 5 to 8 percent silicon by dry weight, primarily as soluble silicic acid. However, the bioavailability of silicon from horsetail extract varies significantly with preparation method: standardized aqueous extracts have approximately 5 to 10 percent silicon bioavailability, while some commercial products claim much higher values without supporting data. Horsetail also contains thiaminase (an enzyme that degrades thiamine), making long-term high-dose use problematic without thiamine co-supplementation. Choline-stabilized orthosilicic acid (ch-OSA) supplements bypass the extraction variability issue and have the most bioavailability data.
- •Silicon is an essential trace element for normal connective tissue development in animals, with silicon deficiency in animal studies producing skeletal deformities, reduced collagen content in bone and connective tissue, abnormal cartilage development, and impaired glycosaminoglycan synthesis. However, frank silicon deficiency in humans has not been documented, as dietary silicon intake from food and water (typically 20 to 50 mg/day) appears sufficient to prevent obvious deficiency symptoms. Supplementation is therefore targeting optimization above the deficiency threshold rather than correcting a documented deficiency.
- •Skin quality endpoints have been explored in ch-OSA trials. The Barel et al. study and a subsequent 20-week trial by Barel et al. (2006) found improvements in skin roughness, microrelief, and self-reported skin firmness with ch-OSA supplementation, with skin surface profiles showing reduced wrinkle depth. These improvements were modest and the clinical significance is uncertain, but the consistency with the proposed collagen-supportive mechanism of silicon suggests a genuine biological effect on skin extracellular matrix quality, likely operating through COL1A1-encoded type I collagen support.
Basic Information
- Name
- Silica
- Also Known As
- siliconsilicon dioxideSiO2orthosilicic acidOSAch-OSA (choline-stabilized orthosilicic acid)silicic acidbioavailable siliconhorsetail silicaEquisetum arvense extractcolloidal silicamonomethylsilanetriol
- Category
- Trace mineral / connective tissue cofactor
- Bioavailability
- Silicon bioavailability varies dramatically by form and source. Orthosilicic acid (OSA, Si(OH)4), the monomeric soluble form in water, achieves approximately 50 to 65 percent intestinal absorption, making it the gold standard for bioavailability. Choline-stabilized orthosilicic acid (ch-OSA, available as BioSil and similar products) stabilizes OSA in a form that maintains high bioavailability and provides consistent plasma silicon elevation. Plant silica from phytoliths (the structural silica in plant cell walls and grains) has very low bioavailability (approximately 1 to 5 percent) because the crystalline silica matrix resists dissolution in the GI tract. Horsetail (Equisetum arvense) extracts contain a mixture of soluble and insoluble silicon forms with intermediate bioavailability (approximately 5 to 15 percent depending on extraction method). Silicon from beverages, particularly beer and mineral water, has higher bioavailability than solid food sources. Colloidal silica has intermediate bioavailability (approximately 20 to 30 percent). Age, gastric pH, and co-ingested minerals do not substantially alter silicon absorption from high-bioavailability sources.
- Half-Life
- Plasma orthosilicic acid has a short half-life of approximately 2 to 4 hours, with rapid urinary excretion accounting for the clearance. Silicon does not significantly accumulate in most soft tissues at supplemental doses. However, bone and connective tissue concentrations reflect long-term dietary silicon status with a slower turnover, consistent with silicon incorporation into the organic matrix of bone collagen and cartilage proteoglycans. Repeated daily supplementation is required to maintain elevated plasma orthosilicic acid concentrations; twice-daily dosing produces more stable plasma levels than single daily doses.
Primary Mechanisms
Prolyl hydroxylase cofactor activity, supporting hydroxylation of proline to hydroxyproline in the COL1A1 collagen triple helix assembly
Lysyl oxidase activity support, facilitating collagen fibril cross-linking between lysine and hydroxylysine residues
Glycosaminoglycan synthesis promotion in chondrocytes and fibroblasts, supporting cartilage proteoglycan production
Hydroxyapatite crystal nucleation and growth support at the collagen matrix of bone
COL1A1 and COL3A1 gene expression upregulation in osteoblasts and dermal fibroblasts at physiological concentrations
Elastin synthesis support in dermal fibroblasts through orthosilicic acid signaling
Aluminum chelation and urinary aluminum excretion promotion, potentially reducing aluminum accumulation in bone and neural tissue
Antioxidant activity of silicon-containing compounds in certain food matrices
Quick Safety Summary
Clinical trials have primarily used ch-OSA (choline-stabilized orthosilicic acid) at 10 mg/day of elemental silicon, corresponding to approximately 55 mg of ch-OSA per day. Horsetail extract doses providing 5 to 20 mg silicon per day are used in many commercial products. The EFSA (European Food Safety Authority) has established a tolerable upper intake level for bioavailable silicon of approximately 700 mg silicon/day from food and supplements combined, based on absence of adverse effects in humans at these levels. Dietary silicon intake from food typically provides 20 to 50 mg/day, and supplemental doses of 5 to 50 mg silicon/day are well within the safety margin. Long-term safety data for ch-OSA at 10 mg silicon/day has been reported up to 9 months without significant adverse effects.
Kidney disease (CKD stages 3 to 5): silicon is cleared renally, and in severe renal impairment, silicon accumulation could theoretically occur; use with medical supervision in patients with eGFR below 30 mL/min, Horsetail extract specifically - thiamine (vitamin B1) deficiency risk: horsetail contains thiaminase, an enzyme that degrades thiamine; long-term high-dose horsetail extract use (more than 3 months at doses above 20 mg silicon/day from horsetail) can cause thiamine deficiency, particularly in individuals with already marginal thiamine status (alcoholics, malnutrition); thiamine supplementation is advisable with horsetail-based silicon sources, Silicosis or pulmonary silica exposure: individuals with occupational crystalline silica (quartz) inhalation exposure should not interpret dietary orthosilicic acid supplementation as comparable to their occupational exposure; dietary orthosilicic acid is biologically distinct from inhaled crystalline silica, which causes silicosis through a completely different inflammatory lung mechanism, Pregnancy and breastfeeding: insufficient safety data exist for silicon supplementation above normal dietary levels during pregnancy; standard dietary silicon intake is likely safe, but high-dose supplementation should be avoided
Overview
Silicon is the second most abundant element in the Earth's crust and is ubiquitous in food, soil, and water, yet its biological role in the human body remains incompletely characterized compared to other trace minerals like zinc, selenium, and iron. Silicon is found in virtually all human tissues, with the highest concentrations in bone, aorta, trachea, tendon, and skin, precisely the tissues richest in collagen and connective tissue matrix components. This anatomical distribution strongly suggested a biological role in connective tissue assembly before the molecular mechanisms were characterized. As orthosilicic acid (Si(OH)4), the bioavailable monomeric form, silicon is proposed to support prolyl hydroxylase and lysyl oxidase enzyme activities that are critical for collagen triple helix stability and collagen fibril cross-linking, glycosaminoglycan production by chondrocytes and fibroblasts, and hydroxyapatite crystal formation in bone. Silicon deficiency in chickens, rats, and other animals produces reproducible skeletal deformities, reduced collagen content in connective tissue, and impaired glycosaminoglycan synthesis, confirming an essential biological role, though frank silicon deficiency in humans has not been documented.
The molecular mechanism most strongly supported for silicon's biological activity involves its role as an enzyme cofactor in collagen post-translational modification. Type I collagen, encoded by the COL1A1 and COL1A2 genes, is the most abundant protein in the human body and the primary structural component of bone, skin, tendon, ligament, and cornea. The assembly of functional collagen fibrils from procollagen chains requires sequential enzymatic steps including prolyl hydroxylase (which converts proline to hydroxyproline, essential for the stability of the collagen triple helix), lysyl hydroxylase (which converts lysine to hydroxylysine), and lysyl oxidase (which oxidizes lysine and hydroxylysine residues to form the covalent aldehyde cross-links that give collagen tensile strength). Silicon is proposed to be required for the activity of these enzymes, either as a direct cofactor or through structural support of the enzyme-substrate interaction. In vitro studies show that orthosilicic acid at 10 to 50 micromolar concentrations stimulates type I collagen gene expression in human fibroblasts and osteoblasts and increases lysyl oxidase activity, providing cellular-level mechanistic support for the dietary silicon-collagen quality hypothesis.
The bioavailability challenge is the central pharmacological issue for silicon supplementation. The chemical form of silicon determines how much is actually absorbed and reaches tissues. The most bioavailable form is orthosilicic acid (OSA), the monomeric soluble form in which silicon circulates in water and body fluids. At gastric pH, silicon from food and supplements converts to orthosilicic acid if solubilized, but the efficiency of this conversion varies by source: plant phytolith silica (rigid crystalline silica bodies in plant cell walls) dissolves very slowly and is largely excreted intact; horsetail extract contains a mixture of soluble and insoluble silicon forms; and choline-stabilized orthosilicic acid (ch-OSA, available as BioSil, 5-MTHF silicon, and similar products) is specifically formulated to deliver orthosilicic acid in a stable, highly bioavailable form. Clinical trials using ch-OSA have achieved plasma orthosilicic acid elevations of 50 to 100 percent above baseline at 10 mg silicon/day doses, confirming effective absorption and tissue distribution. The pharmacokinetic superiority of ch-OSA over horsetail and colloidal silica for achieving tissue-relevant silicon concentrations makes formulation selection critical for efficacy.
The clinical evidence base for silicon supplementation is modest compared to better-established bone and connective tissue interventions, and it is important to characterize the evidence accurately without overstating benefits. The most rigorous clinical evidence comes from ch-OSA trials in hair and nail quality (Barel et al., 2005, PMID 16205921), which demonstrated statistically significant improvements in hair tensile strength and nail brittleness at 10 mg silicon/day over 9 months. Epidemiological associations between dietary silicon intake and bone mineral density (Jugdaohsingh et al., 2004, PMID 15184105) are suggestive but do not establish causation. Randomized trials of silicon supplementation for bone density in osteoporotic populations are limited and underpowered. Skin quality endpoints have shown improvements in small trials. The overall picture is of a trace mineral with plausible mechanisms, modest clinical evidence for specific endpoints (hair, nail, skin quality), and insufficient evidence for definitive recommendations in bone health or joint disease management. Silicon supplementation is best positioned as a complementary trace mineral for connective tissue support, particularly for hair and nail quality, rather than a primary intervention for any specific disease.
Core Health Impacts
- • Hair quality, strength, and thickness: The most consistently demonstrated clinical benefit of silica supplementation is improvement in hair mechanical properties. The randomized trial by Barel et al. (2005, Archives of Dermatological Research, PMID 16205921, n=48) found that ch-OSA 10 mg/day for 9 months significantly improved hair tensile strength (elastic gradient increased by approximately 13 percent) and reduced hair brittleness compared to placebo in women with self-reported fine hair. A separate assessment of hair morphology found a trend toward increased hair cross-sectional area (hair thickness), consistent with improved collagen matrix support in the hair follicle dermal papilla and perifollicular connective tissue. Hair shaft quality is determined by the protein composition and structural organization of the hair cortex, and the collagen-rich connective tissue surrounding hair follicles influences the differentiation environment for hair matrix cells, providing a plausible indirect mechanism for silicon effects on hair quality.
- • Nail strength and quality: Nail brittleness, fragility, and surface irregularity are common complaints that may reflect impaired connective tissue quality, collagen structure in the nail bed, or local trace mineral insufficiency. The Barel et al. (2005) ch-OSA trial found that nail brittleness scores improved significantly in the silicon group compared to placebo over 9 months, with participants reporting reduced nail breakage and improved nail surface regularity. Nails are primarily composed of hard keratin, but the nail bed is a collagen-rich connective tissue structure that provides the scaffold for nail attachment and growth; silicon effects on nail quality are likely mediated through improved collagen integrity in the nail bed rather than direct effects on keratin structure.
- • Skin quality and collagen support: Two ch-OSA trials by Barel and colleagues (2005, 2006) examined skin quality endpoints including roughness, microrelief depth, and self-reported firmness. Both trials found improvements in objective skin surface measurements with ch-OSA supplementation at 10 mg/day over 12 to 20 weeks, with reductions in surface roughness and microrelief scores consistent with improved skin matrix quality. The mechanism is proposed to involve silicon supporting COL1A1-type I collagen synthesis and cross-linking in the dermal extracellular matrix, as skin elasticity and firmness depend primarily on the quality of the collagen network in the dermis. These effects are modest and limited to laboratory measurements of skin texture; no published randomized trial has assessed clinically meaningful endpoints like wound healing rate or skin wrinkle scoring using validated tools in large populations.
- • Bone mineral density and structural integrity: The most epidemiologically compelling evidence for silicon in bone health comes from the Framingham Offspring Study, which found that dietary silicon intake was positively associated with cortical bone mineral density in men and premenopausal women, with the association being statistically significant and dose-responsive (Jugdaohsingh et al., 2004, PMID 15184105). The proposed mechanism involves silicon participating in the cross-linking of collagen within the bone organic matrix and supporting hydroxyapatite crystal formation; bone mineral is deposited within the collagen framework, and disruption of collagen organization impairs the mechanical properties of bone independent of mineral content. However, randomized controlled trials of silicon supplementation for fracture prevention or BMD improvement in clinical populations are lacking, and the evidence falls short of supporting silicon as a primary intervention for osteoporosis management.
- • Cartilage and joint connective tissue support: Silicon concentrations are highest in the articular cartilage and joint connective tissue among body compartments, suggesting a structural role in cartilage extracellular matrix organization. Type II collagen (encoded by COL2A1) is the primary collagen of articular cartilage, but type I collagen (COL1A1) is abundant in periarticular connective tissue, tendons, and the fibrocartilage of the knee and intervertebral disc. Silicon deficiency in animal studies produces abnormal articular cartilage development with reduced glycosaminoglycan content, supporting a role in proteoglycan and collagen matrix assembly. Small observational studies in osteoarthritis patients find lower serum silicon levels compared to healthy controls, but whether this reflects causation or consequence of joint disease is unknown, and no randomized trial has tested silicon supplementation as a cartilage-protective intervention.
- • Collagen synthesis support and glycosaminoglycan production: Cell culture studies using osteoblasts and dermal fibroblasts provide mechanistic evidence for silicon effects on collagen synthesis. Orthosilicic acid at concentrations of 10 to 50 micromolar (physiologically achievable with supplementation) has been shown to increase type I collagen gene expression and protein production in human osteoblast-like cells (SaOS-2) and dermal fibroblasts, with corresponding increases in downstream matrix components including osteocalcin and bone sialoprotein in osteoblasts, and elastin and glycosaminoglycans in dermal fibroblasts. These in vitro findings support the proposed mechanism of silicon as a cofactor for prolyl hydroxylase and lysyl oxidase activity in collagen maturation, but cell culture concentrations may not reflect the concentrations achievable at tissue sites in supplemented humans.
- • Trace mineral function and systemic silicon homeostasis: Silicon is the second most abundant element in the Earth''s crust and is ubiquitous in the human diet through plant foods (cereals, vegetables), drinking water, and beer (where fermentation releases silicic acid from barley). Typical dietary silicon intake is 20 to 50 mg/day, with beer and high-fiber plant foods as major contributors. Silicon is absorbed as orthosilicic acid primarily in the small intestine (absorption efficiency approximately 25 to 50 percent depending on form), circulates briefly in plasma (clearance half-life approximately 2 to 3 hours), and is excreted almost entirely in urine. Tissue silicon concentrations decline with age, and this age-related decline parallels reductions in collagen content, glycosaminoglycan production, and bone quality, providing a correlative (though not necessarily causal) link between silicon status and age-related connective tissue deterioration.
Gene Interactions
Key Gene Targets
COL1A1
Orthosilicic acid (the bioavailable form of silicon) upregulates COL1A1 gene expression in human osteoblasts and dermal fibroblasts at physiologically achievable concentrations (10 to 50 micromolar), and supports the enzymatic post-translational modifications required for type I collagen fibril formation, including prolyl hydroxylase-mediated proline hydroxylation and lysyl oxidase-mediated collagen fibril cross-linking. These mechanisms support the structural integrity of the COL1A1-encoded collagen alpha-1(I) chain in bone, skin, tendon, and other connective tissues, providing a mechanistic rationale for silicon's proposed role in connective tissue quality and its clinical associations with hair, nail, and skin improvements in supplementation trials.
Safety & Dosing
Contraindications
Kidney disease (CKD stages 3 to 5): silicon is cleared renally, and in severe renal impairment, silicon accumulation could theoretically occur; use with medical supervision in patients with eGFR below 30 mL/min
Horsetail extract specifically - thiamine (vitamin B1) deficiency risk: horsetail contains thiaminase, an enzyme that degrades thiamine; long-term high-dose horsetail extract use (more than 3 months at doses above 20 mg silicon/day from horsetail) can cause thiamine deficiency, particularly in individuals with already marginal thiamine status (alcoholics, malnutrition); thiamine supplementation is advisable with horsetail-based silicon sources
Silicosis or pulmonary silica exposure: individuals with occupational crystalline silica (quartz) inhalation exposure should not interpret dietary orthosilicic acid supplementation as comparable to their occupational exposure; dietary orthosilicic acid is biologically distinct from inhaled crystalline silica, which causes silicosis through a completely different inflammatory lung mechanism
Pregnancy and breastfeeding: insufficient safety data exist for silicon supplementation above normal dietary levels during pregnancy; standard dietary silicon intake is likely safe, but high-dose supplementation should be avoided
Drug Interactions
Aluminum-containing antacids: silicon may form complexes with aluminum in the GI tract, reducing aluminum absorption; this is potentially beneficial for reducing aluminum accumulation but may also reduce antacid efficacy; separate doses by 2 hours
Calcium and magnesium supplements: high-dose calcium and magnesium may competitively inhibit silicon absorption if co-administered; space silicon supplements 1 to 2 hours from mineral supplements
Fluoride supplements: silicon and fluoride compete for incorporation into bone hydroxyapatite; high silicon intake may reduce fluoride incorporation into bone, which could theoretically affect enamel formation in high-dose fluoride supplementation contexts
Diuretics: thiazide diuretics may enhance urinary silicon excretion, potentially reducing tissue silicon concentrations; monitor for reduced efficacy of silicon supplementation in patients on chronic thiazide diuretics
Iron supplements: insoluble silicon compounds may bind ferric iron in the GI tract, potentially reducing iron absorption; space silicon and iron supplements by 2 to 3 hours
Antibiotics: no significant pharmacokinetic interactions with antibiotics are established; silicon is not significantly metabolized by gut bacteria or hepatic CYP enzymes
Common Side Effects
GI discomfort (mild nausea, belching) with colloidal silica or horsetail extract in some individuals; generally minimal with ch-OSA formulations
Thiamine deficiency symptoms with long-term high-dose horsetail extract (muscle weakness, peripheral neuropathy, confusion); rare at typical supplement doses with thiamine co-supplementation
No significant adverse effects have been reported at doses up to 700 mg silicon/day from dietary and supplement sources combined in published safety assessments
Studied Doses
Clinical trials have primarily used ch-OSA (choline-stabilized orthosilicic acid) at 10 mg/day of elemental silicon, corresponding to approximately 55 mg of ch-OSA per day. Horsetail extract doses providing 5 to 20 mg silicon per day are used in many commercial products. The EFSA (European Food Safety Authority) has established a tolerable upper intake level for bioavailable silicon of approximately 700 mg silicon/day from food and supplements combined, based on absence of adverse effects in humans at these levels. Dietary silicon intake from food typically provides 20 to 50 mg/day, and supplemental doses of 5 to 50 mg silicon/day are well within the safety margin. Long-term safety data for ch-OSA at 10 mg silicon/day has been reported up to 9 months without significant adverse effects.
Mechanism of Action
Orthosilicic Acid and Collagen Biosynthesis
Silicon acts as a biological cofactor in connective tissue assembly primarily through its interactions with the enzymes and substrates of the collagen biosynthetic pathway. Type I collagen, the product of the COL1A1 and COL1A2 genes, undergoes extensive post-translational modification before forming mature tensile fibrils. The key enzymatic steps requiring cofactors are prolyl 4-hydroxylase (which converts proline to 4-hydroxyproline in the Gly-Pro-Hyp repeating sequence, essential for triple helix thermostability), lysyl hydroxylase (which generates hydroxylysine required for glycosylation and cross-linking), and lysyl oxidase (which oxidizes lysine and hydroxylysine to form the reactive aldehyde groups that spontaneously condense to form intrafibrillar cross-links).
Orthosilicic acid at concentrations of 10 to 50 micromolar has been shown in cell culture studies to increase prolyl 4-hydroxylase activity and type I collagen gene (COL1A1) expression in human osteoblast-like cells and dermal fibroblasts. The proposed mechanism involves silicon interaction with the hydroxyl-rich substrate binding sites of prolyl hydroxylase, either as a structural facilitator of enzyme conformation or as a cofactor competing with substrate inhibition. Silicon also appears to support lysyl oxidase activity, the enzyme responsible for the covalent cross-links that determine the tensile strength and mechanical durability of collagen fibrils. Without adequate cross-linking, individual collagen fibrils slip past each other under mechanical load, reducing tissue tensile strength. This explains why silicon-deficient animals show reduced collagen content and abnormal connective tissue mechanics despite apparently normal collagen biosynthesis.
Glycosaminoglycan and Proteoglycan Synthesis Support
Silicon deficiency in experimental animals consistently produces reduced glycosaminoglycan (GAG) content in articular cartilage and connective tissue, suggesting a role in proteoglycan synthesis or sulfation. Glycosaminoglycans (including heparan sulfate, chondroitin sulfate, dermatan sulfate, and keratan sulfate) are the linear polysaccharide chains attached to proteoglycan core proteins (aggrecan, versican, decorin, biglycan) that provide hydration capacity and compressive resilience to cartilage and extracellular matrix. The mechanism by which silicon influences GAG synthesis is not fully characterized, but orthosilicic acid at physiological concentrations has been shown to upregulate aggrecan gene expression in chondrocyte cultures and to increase the sulfate content of GAG chains produced by fibroblasts, suggesting effects on both GAG chain length and sulfation pattern.
Bone Mineralization and Hydroxyapatite
The mineral phase of bone (hydroxyapatite, Ca10(PO4)6(OH)2) is deposited within the organic matrix framework of type I collagen. Silicon is found in newly formed bone mineral at concentrations substantially higher than in mature bone, and silicon concentrations are highest at the sites of active bone formation (osteoid), declining as mineralization matures. This distribution suggests a role in initiating or accelerating hydroxyapatite crystal nucleation at specific sites within the collagen matrix. Silicon may function by modifying the surface charge and crystal growth kinetics of calcium phosphate phases at the organic-mineral interface, creating nucleation sites that template subsequent hydroxyapatite deposition. The consequence of silicon insufficiency at these sites would be slower or disorganized bone mineral deposition, potentially explaining the reduced bone mineral density observed in silicon-deficient animals.
Cellular Signaling in Osteoblasts and Fibroblasts
Beyond direct enzyme cofactor activity, orthosilicic acid has been shown to activate specific cellular signaling pathways that regulate collagen gene expression. In osteoblasts, si(OH)4 appears to activate MAPK/ERK signaling, which increases expression of the transcription factors SP1 and AP-1 that drive COL1A1 and osteocalcin gene transcription. In dermal fibroblasts, orthosilicic acid increases both COL1A1 and elastin gene expression and promotes fibroblast proliferation at physiological concentrations, suggesting a growth-promoting effect on the cells responsible for maintaining dermal matrix quality. These cellular responses are consistent with the clinical observations of improved skin, hair, and nail quality in silicon supplementation trials, where the improvements are proposed to reflect enhanced fibroblast activity in the dermal, perifollicular, and nail bed connective tissue.
Clinical Evidence
Hair, Nail, and Skin Quality
The most rigorously conducted clinical evidence for silicon supplementation comes from the research program of Barel, Calomme, and colleagues using ch-OSA. The primary hair quality trial (PMID 16205921) was a randomized double-blind placebo-controlled study of 48 women with self-reported fine hair, comparing ch-OSA 10 mg silicon/day to placebo for 9 months. Hair mechanical properties were measured using tensile testing: the elastic gradient (a measure of stiffness) and break load (tensile strength at fracture) both improved significantly in the silicon group. Nail brittleness scores self-reported by participants also improved significantly. The follow-up skin quality trial (PMID 17004983) in 50 women over 20 weeks showed improvements in objective skin surface microrelief measurements and self-reported firmness, with biopsy-measured collagen density increased in the silicon group compared to placebo.
Bone Mineral Density
The epidemiological evidence from the Framingham Offspring Study (Jugdaohsingh et al., 2004, PMID 15184105) provides the strongest population-level support for silicon in bone health. Among 2,847 participants, dietary silicon intake was independently associated with cortical BMD at the femoral neck in men and premenopausal women after adjustment for age, BMI, calcium intake, and physical activity (p less than 0.05). Notably, this association was absent in postmenopausal women, suggesting that estrogen may potentiate silicon effects on bone formation. The absolute association was approximately 10 percent higher cortical BMD per quartile of silicon intake, which is clinically meaningful but requires confirmation in intervention trials. No large randomized trial of silicon supplementation for fracture risk reduction has been published, limiting the evidence base for definitive recommendations.
Dosing Guidance
For hair, nail, and skin quality: ch-OSA providing 10 mg silicon/day, taken with morning and evening meals; treat for a minimum of 6 to 9 months before assessing response; combine with vitamin C (500 to 1,000 mg/day) to optimize prolyl hydroxylase activity. For bone health support as a complementary intervention: ch-OSA 10 to 25 mg silicon/day combined with calcium 1,000 to 1,200 mg/day and vitamin D3 2,000 to 4,000 IU/day; silicon alone is insufficient for bone density management. For joint connective tissue support: ch-OSA 10 to 25 mg silicon/day combined with collagen peptides, glucosamine, and vitamin C for a comprehensive connective tissue support protocol; clinical evidence for silicon in joint disease is limited but mechanistically supported.
Getting the Most from Silica
Choose choline-stabilized orthosilicic acid (ch-OSA) formulations rather than crude horsetail extract for maximum bioavailability and consistent dosing; ch-OSA achieves 50 to 65 percent absorption compared to 5 to 15 percent for typical horsetail extracts, making it 4 to 10 times more efficient for delivering silicon to tissues
Hair and nail quality endpoints are the most evidence-supported applications for silica supplementation; set realistic expectations of 3 to 6 months before visible improvement, and 9 to 12 months for the full trial duration used in published clinical research
Silica works synergistically with vitamin C and copper for collagen synthesis: vitamin C is required as a co-factor for prolyl hydroxylase (the same enzyme silicon supports), and copper is essential for lysyl oxidase activity that cross-links collagen fibrils; ensuring adequate intake of all three nutrients optimizes the collagen assembly pathway
Collagen peptide supplements (providing hydroxyproline and proline substrates) combined with silicon supplementation may provide complementary support: collagen peptides deliver amino acid substrates for new collagen synthesis while silicon supports the enzymatic processing of those substrates into mature cross-linked fibrils
If using horsetail extract products, supplement thiamine (vitamin B1) at 25 to 100 mg/day, particularly if the horsetail preparation is unfermented or uses raw plant material rather than a standardized extract; thiaminase activity varies by preparation method
Silicon from mineral water (particularly silicic acid-rich brands containing greater than 30 mg/L silicon) provides modest but bioavailable silicon intake as part of normal hydration; some brands specifically marketed for silicon content (Fiji, Volvic, some European mineral waters) provide meaningful supplemental silicon equivalent
For skin quality, silicon supplementation is most logically combined with other dermal matrix support interventions including marine collagen peptides, vitamin C, zinc, and adequate protein intake; silicon alone is unlikely to produce dramatic skin improvements without the substrate availability for collagen synthesis
Biotin is sometimes combined with silica in hair, skin, and nail supplements; while biotin has established roles in keratin synthesis and is deficient in some individuals causing hair loss, the biotin deficiency mechanism is entirely distinct from the silicon-collagen mechanism; combining them addresses different aspects of connective tissue and keratin quality
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Randomized double-blind placebo-controlled trial of ch-OSA at 10 mg silicon/day over 9 months in 48 women with fine hair, demonstrating significant improvements in hair tensile strength (elastic gradient and break load) and nail brittleness, providing the most rigorous clinical evidence for silicon supplementation in hair and nail quality endpoints.
Comprehensive review characterizing the bioavailability of silicon from different dietary and supplemental sources, establishing that orthosilicic acid from water and beverages achieves the highest absorption (approximately 50 percent), while plant phytolith silica achieves less than 5 percent, and providing the pharmacokinetic framework for evaluating silicon supplement formulations.
Epidemiological analysis from the Framingham Offspring Study (n=2,847) finding that dietary silicon intake is positively and significantly associated with cortical bone mineral density in men and premenopausal women but not postmenopausal women, providing the most important population-level evidence for a silicon-bone relationship in humans.
In vitro study demonstrating that orthosilicic acid at 10 to 50 micromolar concentrations significantly increases type I collagen gene expression and prolyl hydroxylase activity in human dermal fibroblasts and osteoblast-like cells, establishing the cellular mechanistic basis for silicon support of COL1A1-mediated collagen synthesis.
Review establishing silicon as an essential cofactor for multiple enzymes involved in connective tissue assembly, including evidence from silicon-deficient animal studies showing reduced glycosaminoglycan content in cartilage and impaired collagen cross-linking, providing the experimental foundation for silicon supplementation rationale in connective tissue health.
Foundational study establishing silicon as an essential element for connective tissue development in chickens, demonstrating that silicon-deficient chicks develop skeletal deformities, reduced collagen content, and impaired cartilage formation, and that silicon deficiency is correctable by dietary silicon supplementation, establishing the essentiality of silicon for connective tissue in animals.
Twenty-week randomized trial of ch-OSA at 10 mg silicon/day in 50 women, demonstrating improvements in skin surface microrelief, roughness, and self-reported skin firmness, with skin biopsy data showing increased collagen content compared to placebo, providing the primary clinical evidence for silicon supplementation effects on dermal collagen quality.
Systematic bioavailability study measuring urinary silicon excretion as a proxy for absorption from multiple silicon sources, confirming that silicon in beer and water achieves approximately 50 percent bioavailability, horsetail extract approximately 10 percent, and that ch-OSA achieves consistently high bioavailability with less inter-individual variation than plant-derived sources.
Review summarizing the biological evidence for silicon in bone health and evaluating the clinical data for silicon supplementation in postmenopausal women, concluding that while mechanistic and epidemiological evidence supports a role for silicon in bone quality, randomized trial evidence for fracture prevention is lacking and silicon should be considered a complementary rather than primary intervention for osteoporosis.